Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mucosal adjuvants.

L Stevceva1, M G Ferrari

  • 1Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson Medical College, Jefferson Alumni Hall, Room 219, 1020 Locust St., Philadelphia, PA 19107, USA. lstevceva@yahoo.com

Current Pharmaceutical Design
|March 22, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of the difference between mean corpuscular haemoglobin concentration and mean cellular haemoglobin concentration in canine complete blood count assessed with an automated haematology analyser.

The Journal of small animal practice·2025
Same author

Toll-like receptor agonists as adjuvants for HIV vaccines.

Current medicinal chemistry·2011
Same author

Update on HIV vaccines: which way now?

Current medicinal chemistry·2011
Same author

The GP120 molecule of HIV-1 and its interaction with T cells.

Current medicinal chemistry·2010
Same author

Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques.

Mucosal immunology·2008
Same author

Impairment of Gag-specific CD8(+) T-cell function in mucosal and systemic compartments of simian immunodeficiency virus mac251- and simian-human immunodeficiency virus KU2-infected macaques.

Journal of virology·2001
Same journal

Role of Phenolic Nanocompounds in Inflammatory Disorders: Current View and Future Aspects.

Current pharmaceutical design·2026
Same journal

Overcoming Physiological Barriers in Brain Tumor Therapy: Advances in Nanomedicine, Ultramolecular Pharmaceuticals, and Targeted Drug Delivery.

Current pharmaceutical design·2026
Same journal

Breathing Life into Research: The Transformative Potential of Lung-on-a-Chip Technology.

Current pharmaceutical design·2026
Same journal

Cross-Tissue Transcriptome-Wide Association Study Prioritizes Candidate Genes and Compound-Associated Signatures for Osteoarthritis.

Current pharmaceutical design·2026
Same journal

Emerging Role of AI in Gastroenterology and Hepatology: Revolutionizing Medical Device-Assisted Diagnosis.

Current pharmaceutical design·2026
Same journal

Nanostructured Lipid Carriers in Drug Targeting: Characterization, Patents, and Recent Innovations.

Current pharmaceutical design·2026
See all related articles

Mucosal vaccines offer easy administration and cost-effectiveness for mass vaccination. Adjuvants like cytokines and chemokines are crucial for enhancing both mucosal and systemic immune responses, overcoming a key challenge in vaccine development.

Area of Science:

  • Vaccinology
  • Immunology
  • Biotechnology

Background:

  • Mucosal vaccines are attractive for mass vaccination due to ease of administration and cost-effectiveness.
  • Inducing both mucosal and systemic immunity remains a significant challenge for non-live mucosal vaccines.
  • Adjuvants are essential for enhancing the immunogenicity of mucosal vaccines.

Purpose of the Study:

  • To review the potential of various adjuvants for mucosal vaccines.
  • To explore strategies for enhancing systemic and mucosal immune responses to mucosal vaccines.
  • To identify novel adjuvant candidates for intranasal and edible vaccine formulations.

Main Methods:

  • Literature review of studies on mucosal vaccine adjuvants.
  • Analysis of the mechanisms by which adjuvants enhance immune responses.

Related Experiment Videos

  • Evaluation of the efficacy of different adjuvant classes, including toxins, CpG motifs, cytokines, and chemokines.

    • Main Results:

    • Mutant Escherichia coli labile toxin (CT) and CpG oligodeoxynucleotides are effective mucosal adjuvants.
    • Proinflammatory cytokines (IL-1α, IL-12, IL-18, IL-15) can act as mucosal adjuvants, improving antibody and CTL responses.
    • Chemokines like MCP-1 enhance IgA secretion and CTL responses for DNA vaccines.

    Conclusions:

    • Adjuvants are critical for overcoming the challenge of inducing robust systemic and mucosal immunity with non-live mucosal vaccines.
    • Cytokines and chemokines represent promising novel adjuvant candidates for intranasal and edible vaccine development.
    • Further research into mucosal adjuvants will facilitate the advancement of effective and easily administered vaccines.